Arimoclomol Prospective Doubleblind, Randomised, Placebo-controlled Study in Patients Diagnosed With NiemannPick Disease Type C
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 18 Jul 2017
At a glance
- Drugs Arimoclomol (Primary)
- Indications Niemann-Pick disease type C
- Focus Registrational; Therapeutic Use
- Sponsors Orphazyme
- 07 Jul 2017 Planned End Date changed from 1 Dec 2017 to 1 Jun 2020.
- 07 Jul 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.
- 11 May 2017 According to an Orphazyme media release, data from this study supported by biochemical readouts, will provide the basis for a marketing authorization application at the end of the study.